SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
634Every bit of progress help. Also, I am not sure by what extend NBI-6024 can beMiljenko Zuanic-11/7/2000
633IND re NB-6024 for Type I Diabetes: biz.yahoo.com Tuesday November 7, 10:52 am RCMac-11/7/2000
632Roche was working with MLNM on MC-4 receptor, and they do not need NBIX sub-liceMiljenko Zuanic-10/9/2000
631Thanks MZ - grateful to have the analysis all in one place. do you know other MLuke-10/9/2000
630Thanks Luke. Many pharma and bios are in race to develop selective and specifiMiljenko Zuanic-10/6/2000
629(WO 00/58361) MELANOCORTIN RECEPTOR LIGANDS 05.10.2000 C07K-14/68 Luke-10/6/2000
628Thanks Peter. It is noteworthy that NBIX have significant intellectual and pateMiljenko Zuanic-10/5/2000
627Here's a review article about the subject of the Chen paper: (From the freeBiomaven-10/5/2000
626Oct. 4, 2000--Neurocrine Biosciences, Inc. (Nasdaq:NBIX - news) today announced nigel bates-10/4/2000
625I can't understand why they reported on 5788 at all? I thought that drug isMiljenko Zuanic-10/2/2000
624>> We are encouraged by these results, which clearly show no increase in dscaram(o)uche-10/2/2000
623NBIX announces MS program update on NBI5788 in Nature Medicine article (I'llBiotech Jim-10/2/2000
622Woof!scaram(o)uche-8/31/2000
621Scientists Pinpoint Possible Cause for Debilitating Sleep Disorder Narcolepsy sim1-8/31/2000
620Last year at this time I thought that NBIX was bit short on clinical programs. Miljenko Zuanic-8/29/2000
619Tuesday August 29, 5:03 pm Eastern Time Press Release Neurocrine Biosciences, scaram(o)uche-8/29/2000
618Additional work: Missing Melanocortin-3 Receptor Results in Fat Mice ---------Miljenko Zuanic-8/28/2000
617as we've discussed........ Monday August 28, 6:59 am Eastern Time Press Rescaram(o)uche-8/28/2000
616Thanks, BJ - I hadn't heard about the MLNM use patent. Here are some MC3-R Biomaven-8/17/2000
615Peter- The paper published by Cone et al. is very interesting regarding MC-3.Biotech Jim-8/17/2000
614Interesting. NBIX seems to have been concentrating on melanocortin 4, but they dBiomaven-8/17/2000
613OHSU Researchers Show Brain Receptor May Control Obesity PORTsim1-8/17/2000
612You guys might want to hear this. Very good prospects for NBIX from the technicaTraderXx-8/2/2000
611NBIX agreement re diabetes with Taisho Pharmaceutical: biz.yahoo.com NeurocrineRCMac-7/24/2000
610open label...... Thursday July 20, 8:12 am Eastern Time Company Press Release scaram(o)uche-7/20/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News